Treating tobacco dependence: Review of the best and latest treatment options

Journal of Thoracic Oncology

Volumn 2, Issue 3, 2007, Pages 249-256

  Ebbert, Jon O ^a   Sood, Amit ^a   Hays, J Taylor ^a   Dale, Lowell C ^a   Hurt, Richard D ^a  

^a Mayo Clinic   (United States)

Author keywords

Bupropion; Drug therapy; Nicotine; Smoking cessation; Tobacco use cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; CLONIDINE; COMMIT; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; PLACEBO; STEROID; UNCLASSIFIED DRUG; VARENICLINE;

ANOREXIA NERVOSA; BRAIN INJURY; BULIMIA; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DRUG CONTRAINDICATION; DRUG DEPENDENCE TREATMENT; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; EYE IRRITATION; HEAD INJURY; HUMAN; LOZENGE; LUNG CANCER; MICTURITION DISORDER; MONOTHERAPY; MOUTH IRRITATION; NAUSEA; NICOTINE REPLACEMENT THERAPY; NOSE IRRITATION; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SMOKING CESSATION; THROAT IRRITATION; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA; FEMALE; LUNG TUMOR; MALE; METHODOLOGY; SMOKING;

FEMALE; HUMANS; LUNG NEOPLASMS; MALE; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 34247108185     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318031bca4     Document Type: Article

References (47)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Fiore MC, Bailey WC, Cohen SJ. Treating Tobacco Use and Dependence. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, 2000.
4. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004;CD000146.
5. Dale LC, Hurt RD, Offord KP, et al. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA 1995;274:1353-1358.
6. Benowitz NL, Zevin S, Jacob P. 3rd. Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther 1998;287:958-962.
7. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792-1798.
8. Rigotti NA, Arnsten JH, McKool KM, et al. The use of nicotine-replacement therapy by hospitalized smokers. Am J Prev Med 1999 Nov.;17:255-259.
9. Hurt RD, Dale LC, Croghan GA, et al. Nicotine nasal spray for smoking cessation: pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels. Mayo Clin Proc 1998;73:118-125.
10. Tonnesen P, Norregaard J, Mikkelsen K, et al. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993;269:1268-1271.
11. Rose JE. The role of upper airway stimulation in smoking. Prog Clin Biol Res 1988;261:95-106.
12. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med 2001;135:423-433.
13. Hays JT, Ebbert JO. Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits. CNS Drugs 2003;17:71-83.
14. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-1202.
15. Choi JH, Dresler CM, Norton MR, et al. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 2003;5:635-644.
16. West R, Shiffman S. Effect of oral nicotine dosing forms on cigarette withdrawal symptoms and craving: a systematic review. Psychopharmacology (Berl) 2001;155:115-122.
17. Shiffman S, Dresler CM, Hajek P, et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002;162:1267-1276.
18. Houtsmuller EJ, Henningfield JE, Stitzer ML. Subjective effects of the nicotine lozenge: assessment of abuse liability. Psychopharmacology (Berl) 2003;167:20-27.
19. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63.
20. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55.
21. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71.
22. Wagena EJ, Knipschild P, Zeegers MP. Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 2005;100:317-326.
23. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004;3:CD000058.
24. Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995;24:41-47.
25. Blondal T, Gudmundsson LJ, Olafsdottir I, et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ 1999;318:285-288.
26. Stapleton J. Commentary: Progress on nicotine replacement therapy for smokers. BMJ 1999;318:289.
27. Dale LC, Ebbert JO, Hays JT, et al. Treatment of nicotine dependence. Mayo Clin Proc 2000;75:1311-1316.
28. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-691.
29. ACOG committee opinion. Number 316, October 2005. Smoking cessation during pregnancy. Obstet Gynecol 2005;106:883-888.
30. [Factors influencing long term survival after resection of bronchogenic carcinoma; an analysis of 1,118 cases]. Zhonghua Yi Xue Za Zhi 1974;191:682-686.
31. Fujisawa T, Iizasa T, Saitoh Y, et al. Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas. J Clin Oncol 1999;17:2086-2091.
32. Martins SJ, Pereira JR. Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol 1999;22:453-457.
33. Sioris T, Husgafvel-Pursiainen K, Karjalainen A, et al. Survival in operable non-small-cell lung cancer: role of p53 mutations, tobacco smoking and asbestos exposure. Int J Cancer 2000;86:590-594.
34. Sobue T, Suzuki T, Fujimoto I, et al. Prognostic factors for surgically treated lung adenocarcinoma patients, with special reference to smoking habit. Jpn J Cancer Res 1991;82:33-39.
35. Tammemagi MC, McLaughlin JR, Mullen JB, et al. A study of smoking, p53 tumor suppressor gene alterations and non-small cell lung cancer. Ann Epidemiol 2000;10:176-185.
36. Wolf M, Holle R, Hans K, et al. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer. 1991;63:986-992.
37. Hinds MW, Yang HY, Stemmermann G, et al. Smoking history and lung cancer survival in women. J Natl Cancer Inst 1982;68:395-399.
38. Xavier F, Henn L, Oliveira M, et al. Smoking and its relation to the histological type, survival, and prognosis among patients with primary lung cancer. Rev Paul Med 1996;114:1298-1302.
39. Johnston-Early A, Cohen MH, Minna JD, et al. Smoking abstinence and small cell lung cancer survival. JAMA 1980;244:2175-2179.
40. Richardson GE, Tucker MA, Venzon DJ, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 1993;119:383-390.
41. Kawahara M, Ushijima S, Kamimori T, et al. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. Br J Cancer 1998;78:409-412.
42. Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst 1997;89:1782-1788.
43. Garces YI, Yang P, Parkinson J, et al. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest 2004;126:1733-1741.
44. Moller AM, Villebro N, Pedersen T, et al. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. Lancet 2002;359:114-117.
45. McBride CM, Emmons KM, Lipkus IM. Understanding the potential of teachable moments: the case of smoking cessation. Health Educ Res 2003;18:156-170.
46. Gritz ER, Fingeret MC, Vidrine DJ, et al. Successes and failures of the teachable moment: smoking cessation in cancer patients. Cancer 2006;106:17-27.
47. Hurt RD. Treating tobacco dependence in the medical setting: best practices. Presented at VA in the Vanguard: Building on Success in Smoking Cessation, San Francisco, CA, 2004.